• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:李梦君,刘波,王晓波,李妍,熊山,牟艳玲,解维林.治疗黑色素瘤的新型二芳基衍生物04022a在不同种属肝微粒体中的稳定性及代谢产物分析[J].药学研究,2023,42(7):433-439[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2613次   下载 2948次 本文二维码信息
码上扫一扫!
治疗黑色素瘤的新型二芳基衍生物04022a在不同种属肝微粒体中的稳定性及代谢产物分析
李梦君,刘波,王晓波,李妍,熊山,牟艳玲,解维林
字体:加大+|默认|缩小-
(山东第一医科大学药学院<药物研究所>,先进药物递释系统全国重点实验室,国家卫健委生物技术药物重点实验室,山东省罕少见病重点实验室,山东 济南 250117)
摘要:
目的 采用SD大鼠、人、比格犬的肝微粒体酶,考察新型二芳基衍生物04022a在3个种属肝微粒体中的代谢稳定性,比较代谢的种属差异,并对产生的代谢产物进行筛选与结构表征。方法 将04022a溶解在由NADPH启动的肝微粒体孵育体系中,孵育0 、15 、30 、60 、90 、120 min后,加入等体积的冰甲醇终止反应。采用高效液相色谱法测定04022a的质量浓度,计算各个时间点的剩余药物百分比、体外半衰期(t1/2)和固有清除率(CLint)。采用超高效液相色谱串联飞行时间质谱法对04022a在肝微粒体中的代谢产物进行检测与分析。结果 孵育120 min时,04022a在大鼠、人、比格犬肝微粒体中的剩余药物百分比分别为88.30%、82.15%、98.63%。t1/2分别为770、364、3 465 min,CLint分别为0.001 8、0.003 8、0.000 4 mL•(min•mg)-1。初步判断04022a在3个种属共有5个体外代谢产物。结论 04022a在各种肝微粒体中的代谢稳定性良好,主要代谢转化途径包括脱烷基化、羟基化、脱氢。
关键词:  二芳基衍生物04022a  肝微粒体  代谢稳定性  代谢产物  黑色素瘤
DOI:10.13506/j.cnki.jpr.2023.07.001
基金项目:山东第一医科大学学术提升计划(No.2019LJ003);国家自然科学基金(No.81903473)
出版日期:2023-07-25
Stability and metabolites analysis of a novel diaryl derivative 04022a for melanoma treatment in different species of liver microsomes
LI Mengjun,LIU Bo,WANG Xiaobo,LI Yan,XIONG Shan,MOU Yanling,XIE Weilin
(School of Pharmacy and Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, NHC Key Laboratory of biotechnology drugs (Shandong Academy of Medical Sciences) , Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan 250117, China)
Abstract:
Objective To investigate the metabolic stability of the novel diaryl derivative 04022a in liver microsomes of three species using liver microsomal enzymes from SD rats, humans, and beagles, compare the differences in metabolism among species, and screen and characterize the metabolites produced. Methods 04022a was dissolved in a liver microsome incubation system initiated by NADPH. After incubation for 0, 15, 30, 60, 90 and 120 min, the reaction was terminated by adding the same volume of ice methanol. The mass concentration of 04022a was determined by high performance liquid chromatography. The percentage of remaining drug, in vitro half-life (t1/2) and intrinsic clearance (CLint) were calculated at each time point. The metabolites of 04022a in liver microsomes were detected and analyzed by ultra performance liquid chromatography tandem time-of-flight mass spectrometry. Results After incubation for 120 min, the remaining drug percentages of 04022a in rat, human, and beagle liver microsomes were 88.30%, 82.15% and 98.63%, respectively. t1/2 was 770, 364 and 3 465 min and CLint was 0.001 8, 0.0038 and 0.000 4 mL•(min•mg)-1, respectively. It was preliminarily determined that 04022a had five extraneous metabolites in three species. Conclusion 04022a has good metabolic stability in various liver microsomes. The main metabolic transformation pathways include dealkylation, hydroxylation, dehydrogenation.
Key words:  04022a  Liver microsomes  Metabolic stability  Metabolites
今日访问量:2772    总访问量:55339354
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司